Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH4336 alone or with cadonilimab in advanced solid tumors
CTR20232037Phase 2Active
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SPH4336 in Nonhematologic neoplasms, well-differentiated liposarcoma (WDLS), Liposarcoma, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Oct 2023; status: active.
02
Drugs
SPH4336
03
Conditions
Nonhematologic neoplasmswell-differentiated liposarcoma (WDLS)Liposarcoma
Beyond the preview
Go deeper on CTR20232037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232037.